Trial Profile
Continuous Infusion Piperacillin-Tazobactam for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary) ; Tobramycin
- Indications Bacterial infections; Cystic fibrosis
- Focus Therapeutic Use
- Acronyms PIPE-CF
- 28 Sep 2012 New trial record